Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Adult ADHD
NCT00636818Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Mar 2008; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00636818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636818.